N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.